Cookies?
Library Header Image
LSE Research Online LSE Library Services

Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies

Pan, Yi-Ju, Knapp, Martin ORCID: 0000-0003-1427-0215 and McCrone, Paul R. (2012) Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies. Journal of Affective Disorders, 139 (2). pp. 113-125. ISSN 0165-0327

Full text not available from this repository.

Identification Number: 10.1016/j.jad.2011.07.020

Abstract

Abstract Background Knowledge regarding the relative cost-effectiveness of different antidepressants is crucial for the planning of depression treatment. However, there have been only a small number of reviews of such evidence and synthesizing economic evidence across studies is methodologically challenging. In particular, there have been few reviews of the methods employed in database analyses (studies that use data from real-world practice). Methods Published economic evaluations based on database analyses were systematically reviewed to compare antidepressant treatments in depression. Prospective studies of cost-effectiveness were also reviewed to highlight unanswered questions through comparisons between these two different study designs. Results Forty papers met the criteria and were included. A relatively large number of industry-sponsored evaluations of escitalopram were identified and these found escitalopram to be potentially cost-effective in depression treatment. Evidence of cost-effectiveness differences between other individual SSRIs was not unequivocally established. Inconsistent findings further emerged concerning the cost-effectiveness of SSRIs versus TCAs between retrospective database analyses and prospective studies. Limitations Different outcome measures and cost perspectives make it difficult to make comparisons across studies. Conclusions Evidence regarding the cost-effectiveness of different antidepressantsnext term in depression continues to accumulate. Beyond the efficacy or tolerability data found for newer antidepressants in controlled trials, further research from real-world settings is needed to examine the relative cost-effectiveness of different antidepressant agents.

Item Type: Article
Official URL: http://www.elsevier.com/wps/find/journaldescriptio...
Additional Information: © 2012 Elsevier
Divisions: Social Policy
Personal Social Services Research Unit
Subjects: H Social Sciences > H Social Sciences (General)
H Social Sciences > HC Economic History and Conditions
R Medicine > RS Pharmacy and materia medica
JEL classification: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets
Date Deposited: 09 Sep 2011 15:07
Last Modified: 06 Jan 2024 00:54
URI: http://eprints.lse.ac.uk/id/eprint/38207

Actions (login required)

View Item View Item